Over the last 12 months, Revive Therapeutics (RVV.C) stock slipped 88% from $0.26 per share to a measly $0.03, but is Revive down for the count? Some analysts believe the stock will continue to play in the basement for a while because the foundational work is still being completed, but investors should take heart as once the hammer swings for the last time on the company’s business frame, a distinct upswing will be in the offing. We took a look at Revive and this is what we came up with.

Summing up

Here are some items that should be kept in mind when considering Revive’s potential on the market:

• Development of a Novel Long COVID Rapid Test: Revive Therapeutics has entered into a worldwide exclusive agreement with Lawson Health Research Institute to develop and commercialize a novel diagnostic solution for long COVID. This includes the development of a qELISA laboratory test kit and a lateral flow assay point of care device for rapid testing. The company is also evaluating the potential of this test as a companion to Bucillamine, a potential treatment for long COVID disease​​.
• Phase 3 Clinical Study for Bucillamine in COVID-19 Treatment: Revive Therapeutics announced results of a Phase 3 clinical trial evaluating Bucillamine for mild to moderate COVID-19. The study did not achieve statistical significance on the clinical endpoints. However, there were indications of a positive trend in the Post-dose selection phase of the study, particularly in patients with oxygen saturation below 96% at baseline, where Bucillamine showed a 29.1% improvement over placebo in time to normal oxygen saturation​​.
• Strategic Initiatives for Bucillamine: Based on the data from the Phase 3 study, Revive Therapeutics is pursuing several strategic initiatives for Bucillamine. These include reformulating it for intravenous and inhaled versions, exploring pharmaceutical partnerships for regulatory approvals and new clinical studies, and seeking government support and funding opportunities​​.
• Agreement for Evaluating Bucillamine for Nerve Agent Exposure: Revive Therapeutics has entered into an agreement with Defence Research and Development Canada to evaluate Bucillamine as a potential treatment for nerve agent exposure. The research, funded by the Defence R&D Canada, is expected to begin in early Q1-2024. Bucillamine is being investigated for its potential efficacy against seizure activity and as a treatment for nerve agents or organophosphate pesticide poisoning​​​​.

These developments indicate Revive Therapeutics’ ongoing efforts in various therapeutic areas, including long COVID, COVID-19 treatment, and potential applications for Bucillamine in public health emergencies and rare disorders. Once these initiatives take hold, who knows where the blue sky is on Revive. Remember, do you due diligence and speak with an investment professional before making any investment decisions.